CCK-B Receptor Antagonist 1 is primarily used in research and therapeutic applications targeting the cholecystokinin B (CCK-B) receptor. It is investigated for its potential in treating gastrointestinal disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcers, by modulating gastric acid secretion. Additionally, it is explored in the context of anxiety and panic disorders, as CCK-B receptors are implicated in the regulation of these conditions. In oncology, this antagonist is studied for its role in inhibiting tumor growth, particularly in cancers where CCK-B receptors are overexpressed. Its application in pain management is also under investigation, given its potential to modulate pain pathways. Overall, CCK-B Receptor Antagonist 1 serves as a valuable tool in both clinical and preclinical studies aimed at understanding and treating various receptor-mediated conditions.